XORTX Therapeutics (XRTX) Share-based Compensation (2020 - 2026)
XORTX Therapeutics (XRTX) posted Share-based Compensation of $7816.0 for Q1 2026, up 89.52% on a QoQ basis from $4124.0 in Q4 2025, and down 12.86% year-over-year from $8969.0 in Q1 2025.
XORTX Therapeutics (XRTX) Share-based Compensation (2020 - 2026) Analysis & Trends
XORTX Therapeutics' Share-based Compensation history runs 7 years deep, the most recent figure standing at $7816.0 for Q1 2026.
- Quarterly Share-based Compensation fell 12.86% year-over-year to $7816.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24002.0 (down 69.37% YoY) and the FY2025 annual result came in at $25155.0, down 79.47% from the prior year.
- Share-based Compensation was $7816.0 for Q1 2026 at XORTX Therapeutics, up from $4124.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $333311.8 in Q2 2022 and bottomed at $4124.0 in Q4 2025.
- A 5-year average of $45178.3 and a median of $21850.0 in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation soared 352.97% — and 2023, when it plunged 90.77%.
- XORTX Therapeutics' Share-based Compensation stood at $70905.4 in 2022, then sank by 59.36% to $28815.0 in 2023, then tumbled by 67.01% to $9505.0 in 2024, then sank by 56.61% to $4124.0 in 2025, then soared by 89.52% to $7816.0 in 2026.
- Business Quant data shows XRTX's Share-based Compensation at $7816.0 in Q1 2026, $4124.0 in Q4 2025, and $5117.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 305,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 9.26 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 87.30 Mn |
| 10 | XORTX Therapeutics | 2.91 Bn | 2.91 Bn | - | 7,816.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7,816.00 |
| Mar 31, 2026 | 7,816.00 |
| Dec 31, 2025 | 4,124.00 |
| Dec 31, 2025 | 4,124.00 |
| Sep 30, 2025 | 5,117.00 |
| Sep 30, 2025 | 5,117.00 |
| Jun 30, 2025 | 6,945.00 |
| Jun 30, 2025 | 6,945.00 |
| Mar 31, 2025 | 8,969.00 |
| Mar 31, 2025 | 8,969.00 |
| Dec 31, 2024 | 9,505.00 |
| Dec 31, 2024 | 9,505.00 |
| Sep 30, 2024 | 15,857.00 |
| Sep 30, 2024 | 15,857.00 |
| Jun 30, 2024 | 44,031.00 |
| Jun 30, 2024 | 44,031.00 |
| Mar 31, 2024 | 53,134.00 |
| Mar 31, 2024 | 53,134.00 |
| Dec 31, 2023 | 28,815.00 |
| Dec 31, 2023 | 28,815.00 |